Verrica’s Full Phase III Dataset In Molluscum Shows Greater Separation From Placebo
The latest Phase III data on Verrica’s formulation of cantharidin for the skin disease molluscum show a wider disparity from placebo.
You may also be interested in...
Keeping Track: A Duo Of RTOR Approvals, Thumbs Up For First Oral GLP-1 Treatment, And First Ebola Vaccine Nears US Market
The latest drug development news and highlights from our US FDA Performance Tracker.
After reporting positive pivotal data for VP-102 in the contagious skin disease molluscum, Verrica is looking forward to a 2020 launch, with plans to price for broad access.
Alnylam shows that lumasiran offers similar safety and efficacy in primary hyperoxaluria type 1 patients who are six or younger as it does in older patients. US and EU regulatory decisions loom.